In this study, turmeric's active ingredient (Curcumin) was encapsulated into RGD modified Liposomes (RGD-Lip-Cur) its cytotoxic effect on the breast cancer cell line (MCF-7) was evaluated by MTT, flow cytometry and Caspase assay. Liposomes were characterized using transmission electron microscopy (TEM). Results demonstrated that the liposomes were spherical in shape, ranging from 70 to 100 nm. MTT assay revealed that RGD-Lip-Cur had a significant cytotoxic effect on MCF-7 cells at concentrations of 32, 16 and 4 μg/ml compared to Lip-Cur (P < 0.05) and curcumin (P < 0.01). The apoptosis assay demonstrated that RGD-Lip-Cur induces the apoptosis in MCF-7 cells (39.6% vs 40.2% for initial and secondary apoptosis) significantly more than Lip-Cur (67.7% vs 9.16% for initial and secondary apoptosis) and free curcumin (7.84% vs 38.8% for initial and secondary apoptosis). Moreover, caspase assay showed that RGD-Lip-Cur activates caspase 3/7 compared to Lip-Cur (P < 0.05) and free curcumin (P < 0.01). The RGD-Lip-Cur was similar to the control group and had no significant cytotoxicity effect. It is concluded that RGD-Lip-Cur as a novel carrier have high cytotoxicity effect on breast cancer cell line (MCF-7).
Cancer IAfRo. Latest global cancer data: cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Lyon, France: International Agency for Research on Cancer, 2018.
LaiDVisser-GrieveSYangX.Tumour suppressor genes in chemotherapeutic drug response. Biosci Rep2012;
32: 361–374.
4.
NussbaumerSBonnabryPVeutheyJ-L, et al.
Analysis of anticancer drugs: a review. Talanta2011;
85: 2265–2289.
5.
SeelingerMPopescuRGiessriglB, et al.
Methanol extract of the ethnopharmaceutical remedy smilax spinosa exhibits anti-neoplastic activity. Int J Oncol2012;
41: 1164–1172.
6.
SinhaDBiswasJSungB, et al.
Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets2012;
13: 1799–1819.
7.
GuptaSCSungBKimJH, et al.
Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res2013;
57: 1510–1528.
8.
SongXZhangMDaiE, et al.
Molecular targets of curcumin in breast cancer. Mol Med Rep2019;
19: 23–29.
9.
HegerMvan GolenRFBroekgaardenM, et al.
The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev2014;
66: 222–307.
10.
ChenXZouL-QNiuJ, et al.
The stability, sustained release and cellular antioxidant activity of curcumin nanoliposomes. Molecules2015;
20: 14293–14311.
11.
JinH-HLuQJiangJ-G.Curcumin liposomes prepared with milk fat globule membrane phospholipids and soybean lecithin. J Dairy Sci2016;
99: 1780–1790.
12.
ZouLZhengBZhangR, et al.
Enhancing the bioaccessibility of hydrophobic bioactive agents using mixed colloidal dispersions: curcumin-loaded zein nanoparticles plus digestible lipid nanoparticles. Food Res Int2016;
81: 74–82.
13.
WangCLiuZXuG, et al.
BSA-dextran emulsion for protection and oral delivery of curcumin. Food Hydrocolloids2016;
61: 11–19.
14.
MassaroMAmoratiRCavallaroG, et al.
Direct chemical grafted curcumin on halloysite nanotubes as dual-responsive prodrug for pharmacological applications. Colloids Surf B Biointerf2016;
140: 505–513.
15.
MouslmaniMRosenholmJMPrabhakarN, et al.
Curcumin associated poly (allylamine hydrochloride)-phosphate self-assembled hierarchically ordered nanocapsules: size dependent investigation on release and DPPH scavenging activity of curcumin. RSC Adv2015;
5: 18740–18750.
16.
ZouLLiuWLiuC, et al.
Utilizing food matrix effects to enhance nutraceutical bioavailability: increase of curcumin bioaccessibility using excipient emulsions. J Agric Food Chem2015;
63: 2052–2062.
17.
YallapuMMNageshPKBJaggiM, et al.
Therapeutic applications of curcumin nanoformulations. Aaps J2015;
17: 1341–1356.
AkbarzadehARezaei-SadabadyRDavaranS, et al.
Liposome: classification, preparation, and applications. Nanoscale Res Lett2013;
8: 102.
20.
SalkhoNMPaulVKawakP, et al.
Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy. Artif Cells Nanomed Biotechnol2018;
46: 462–472.
21.
LuLDingYZhangY, et al.
Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII. Int J Nanomedicine2018;
13: 1927–1944.
22.
WenXLiJCaiD, et al.
Anticancer efficacy of targeted shikonin liposomes modified with RGD in breast cancer cells. Molecules2018;
23: 268.
23.
ChengYOuZLiQ, et al.
Cabazitaxel liposomes with aptamer modification enhance tumor‑targeting efficacy in nude mice. Mol Med Report2018;
19: 490–498.
ShanDLiJCaiP, et al.
RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of α v β 3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res2015;
5: 15–26.
26.
WuP-HOnoderaYIchikawaY, et al.
Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells. Int J Nanomedicine2017;
12: 5069–5085.
27.
BrooksPCClarkRAChereshDA.Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science1994;
264: 569–571.
28.
AlipourMBaneshiMHosseinkhaniS, et al.
Recent progress in biomedical applications of RGD‐based ligand: from precise cancer theranostics to biomaterial engineering: a systematic review. J Biomed Mater Res A2020;
108: 839–850.
29.
MousavizadehAJabbariAAkramiM, et al.
Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: a systematic review. Colloids Surf B Biointerfaces2017;
158: 507–517.
30.
OthmanBAGreenwoodCAbuelelaAF, et al.
Correlative light‐electron microscopy shows RGD‐targeted ZnO nanoparticles dissolve in the intracellular environment of triple negative breast cancer cells and cause apoptosis with intratumor heterogeneity. Adv Healthc Mater2016;
5: 1310–1325.
31.
ZhouXLiuH-YZhaoH, et al.
RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment. Onco Targets Ther2018;
11: 5397–5405.
32.
JiangKShenMXuW.Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation. IJN2018;
13: 2561–2569.
33.
NiuRZhangPWangF-Q, et al.
Preparation and purification of novel phosphatidyl prodrug and performance modulation of phosphatidyl nanoprodrug. Bioresour Bioprocess2019;
6: 42.
34.
ChenLLiuYWangW, et al.
Effect of integrin receptor‑targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy. Oncol Lett2015;
10: 77–84.
35.
ZhangQLuLZhangL, et al.
Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide. Sci Rep2016;
6: 19800.
36.
HatakeyamaHAkitaHHarashimaH.The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. Biol Pharm Bull2013;
36: 892–899.
37.
FangYXueJGaoS, et al.
Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery. Drug Deliv2017;
24: 22–32.
38.
BardaniaHShojaosadatiSAKobarfardF, et al.
Optimization of RGD-modified nano-liposomes encapsulating eptifibatide. Iran J Biotechnol2016;
14: 33–40.
39.
BardaniaHShojaosadatiSAKobarfardF, et al.
Encapsulation of eptifibatide in RGD-modified nanoliposomes improves platelet aggregation inhibitory activity. J Thromb Thrombolysis2017;
43: 184–193.
40.
BardaniaHShojaosadatiSAKobarfardF, et al.
RGD-modified nano-liposomes encapsulated eptifibatide with proper hemocompatibility and cytotoxicity effect. Iran J Biotech2019;
17: 8–13.
41.
AliakbariFMohammad-BeigiHRezaei-GhalehN, et al.
The potential of zwitterionic nanoliposomes against neurotoxic alpha-synuclein aggregates in Parkinson's disease. Nanoscale2018;
10: 9174–9185.
42.
AliakbariFShabaniAABardaniaH, et al.
Formulation and anti-neurotoxic activity of baicalein-incorporating neutral nanoliposome. Colloids Surf B Biointerfaces2018;
161: 578–587.
43.
DanaeiMDehghankholdMAtaeiS, et al.
Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics2018;
10: 57.
44.
ZweersMLGrijpmaDWEngbersGH, et al.
The preparation of monodisperse biodegradable polyester nanoparticles with a controlled size. J Biomed Mater Res Part B Appl Biomater2003;
66: 559–566.
FanciullinoRCiccoliniJ.Liposome-encapsulated anticancer drugs: still waiting for the magic bullet?Curr Med Chem2009;
16: 4361–4373.
47.
Adler-AbramovichLBadihi-MossbergMGazitE, et al.
Characterization of peptide‐nanostructure‐modified electrodes and their application for ultrasensitive environmental monitoring. Small2010;
6: 825–831.
48.
OlusanyaTHaj AhmadRIbegbuD, et al.
Liposomal drug delivery systems and anticancer drugs. Molecules2018;
23: 907.
49.
HasanMElkhouryKKahnCJ, et al.
Preparation, characterization, and release kinetics of chitosan-coated nanoliposomes encapsulating curcumin in simulated environments. Molecules2019;
24: 2023.
50.
PreethaPSrinivasaAPushpalathaP.Biphasicdrug delivery in controlled release formulations – a review. Int J Pharm Technol2015;
6: 3046–3060.
51.
TajvarSMohammadiSAskariA, et al.
Preparation of liposomal doxorubicin-graphene nanosheet and evaluation of its in vitro anti-cancer effects. J Liposome Res2019;
29: 163–170.
52.
AskariATajvarSNikkhahM, et al.
Synthesis, characterization and in vitro toxicity evaluation of doxorubicin-loaded magnetoliposomes on MCF-7 breast cancer cell line. J Drug Deliv Sci Technol2020;
55: 101447.
53.
RejinoldNSMuthunarayananMDivyaraniV, et al.
Curcumin-loaded biocompatible thermoresponsive polymeric nanoparticles for cancer drug delivery. J Colloid Interface Sci2011;
360: 39–51.
54.
ChenYWuQZhangZ, et al.
Preparation of curcumin-loaded liposomes and evaluation of their skin permeation and pharmacodynamics. Molecules2012;
17: 5972–5987.
55.
LiZ-lPengS-fChenX, et al.
Pluronics modified liposomes for curcumin encapsulation: sustained release, stability and bioaccessibility. Food Res Int2018;
108: 246–253.
56.
TorchilinVP.Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov2005;
4: 145–160.
57.
KoE-YMoonA.Natural products for chemoprevention of breast cancer. J Cancer Prev2015;
20: 223–231.
58.
Robles-EscajedaEDasUOrtegaNM, et al.
A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol (Dordr)2016;
39: 265–277.
59.
WangRFangD.Detection of phosphatidylserine in the plasma membrane of single apoptotic cells using electrochemiluminescence. RSC Adv2017;
7: 12969–12972.
60.
CrowleyLCScottAPMarfellBJ, et al.
Measuring cell death by propidium iodide uptake and flow cytometry. Cold Spring Harb Protoc2016;
2016: pdb. prot087163.
61.
BaskićDPopovićSRistićP, et al.
Analysis of cycloheximide‐induced apoptosis in human leukocytes: fluorescence microscopy using annexin V/propidium iodide versus acridin orange/ethidium bromide. Cell Biol Int2006;
30: 924–932.
62.
JiaCZhangJYuL, et al.
Antifungal activity of coumarin against Candida albicans is related to apoptosis. Front Cell Infect Microbiol2018;
8: 445.
63.
BanerjeeMSinghPPandaD.Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF‐7 cells. FEBS J2010;
277: 3437–3448.
64.
ShenYWhiteE.p53-dependent apoptosis pathways. Adv Cancer Res2001;
82: 53–85.
65.
RuoslahtiE.RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol1996;
12: 697–715.
66.
HartSHarbottleRCooperR, et al.
Gene delivery and expression mediated by an integrin-binding peptide. Gene Ther1995;
2: 552–554.
67.
MuruganCRayappanKThangamR, et al.
Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy. Sci Rep2016;
6: 1–22.
